Adamas Announces New Employment Inducement Grant
Get Alerts ADMS Hot Sheet
Join SI Premium – FREE
EMERYVILLE, Calif.--(BUSINESS WIRE)-- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees restricted stock units to acquire 57,000 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
About Adamas Pharmaceuticals, Inc.
At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.
Source: Adamas Pharmaceuticals, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210305005009/en/
Media:
Sarah Mathieson
Vice President, Corporate Communications
510-450-3528
[email protected]
Investors:
Peter Vozzo
Westwicke Partners
443-213-0505
[email protected]
Source: Adamas Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Falcon Oil & Gas - Shenandoah South-1H well IP90 Day Flow Rates of 2.9 MMcf/d (normalised to 5.8 MMcf/d)
- Net Asset Value(s)
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!